ENAapplication/xmlftp.sra.ebi.ac.uk/vol1/fastq/ERR447/005/ERR4471595/ERR4471595_2.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/ERR447/004/ERR4471594/ERR4471594_2.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/ERR447/004/ERR4471594/ERR4471594_1.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/ERR447/003/ERR4471593/ERR4471593_1.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/ERR447/005/ERR4471595/ERR4471595_1.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/ERR447/003/ERR4471593/ERR4471593_2.fastq.gzprimaryOK200GenomicsMolecular Pathology, Institute of Pathology & Department of Translational Genomics, University of Colognehttps://www.ebi.ac.uk/ena/browser/view/PRJEB39956ArrayExpressThe experiment investigates transcriptional reponse of EGFR-mut PC9 lung cancer cells following treatment for 24h or 72h with EGFR-inhibitor osimertinib compared to control cells on a single cell level.ENADER/faint little ball, receptor tyrosine-protein kinase erbB-1, d230, D-Egf, proto-oncogene c-ErbB-1, C-erb, Elp-B1, der, Elp-1, mor1, Errb1, dTAFII250, mENA, mereletinib mesylate, EK2-6, EfW1, PIG61, dmTAF[[II]]230, mereletinib mesilate, dmTAF1, Taf230, epidermal growth factor-activated receptor activity, AI552599, c-erbB, EGFr, Egfr, EGF receptor activity, torpedo/Egfr, AZD-9291 mesylate, TOP, Egf-r, d-egf-r, TAF250, EGF-R, Taf200, dTAF[[II]]250, TFIID TAF250, reference sample, cel, cell, top, Torpedo/DER, Taf1p, flb, top/flb, dTAF250, Tagrisso, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide, l(2)57EFa, osimertinib mesilate., 9030024J15Rik, D-EGFR, l(2)57Ea, Mcm, MCM, TAF, NISBD2, osimertinib mesylate, Controlled, AZD9291, DER1, Elp-B1RB1, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide methanesulfonate (1:1), Controlling, dTAF[[II]]230, TAF[[II]]250, Elp, Wa5, l(2)09261, TGF-alpha receptor activity, ERBB, dEGFR1, DEgfr, TAF200, l(3)84Ab, BG:DS00004.13, TAFII-250, TAF250/230, CG10079, Cell, dTAF230, torpedo/egfr, TAFII250, epidermal growth factor receptor activity, wa2, DmelCG10079, p230, TAF[[II]]250/230, TFIID, DER/top, egfr, Taf[[II]]250, HD-33, El, TAF[[II]]230, top/DER, D230010K02Rik, EGFR, DER/EGFR, EGfr, EgfR, dEgfr, DER flb, ERBB1, TAF[II]250, mereletinib, wa-2, Torpedo/Egfr, CG17603, TAF[[II]], Degfr, AZD9291 mesylate, Egf, EFG-R, DmelCG17603, AZD-9291, Taf250, Errp, SR3-5, Erbb, DEGFR, l(2)57DEFa, l(2)05351, Der, DER, dEGFR, transforming growth factor-alpha receptor activity, DmHD-33, DER/torpedo, HER1, TAF230, TAF1DER/faint little ball, receptor tyrosine-protein kinase erbB-1, d230, D-Egf, proto-oncogene c-ErbB-1, C-erb, Elp-B1, der, Elp-1, mor1, Errb1, dTAFII250, mENA, mereletinib mesylate, EK2-6, EfW1, PIG61, dmTAF[[II]]230, mereletinib mesilate, dmTAF1, Taf230, epidermal growth factor-activated receptor activity, AI552599, c-erbB, EGFr, Egfr, EGF receptor activity, torpedo/Egfr, AZD-9291 mesylate, TOP, Egf-r, d-egf-r, TAF250, EGF-R, Taf200, dTAF[[II]]250, TFIID TAF250, reference sample, cel, cell, top, Torpedo/DER, Taf1p, flb, top/flb, dTAF250, Tagrisso, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide, l(2)57EFa, osimertinib mesilate., 9030024J15Rik, D-EGFR, l(2)57Ea, Mcm, MCM, TAF, NISBD2, osimertinib mesylate, Controlled, AZD9291, DER1, Elp-B1RB1, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide methanesulfonate (1:1), Controlling, dTAF[[II]]230, TAF[[II]]250, Elp, Wa5, l(2)09261, TGF-alpha receptor activity, ERBB, dEGFR1, DEgfr, TAF200, l(3)84Ab, BG:DS00004.13, TAFII-250, TAF250/230, CG10079, Cell, dTAF230, torpedo/egfr, TAFII250, epidermal growth factor receptor activity, wa2, DmelCG10079, p230, TAF[[II]]250/230, TFIID, DER/top, egfr, Taf[[II]]250, HD-33, El, TAF[[II]]230, top/DER, D230010K02Rik, EGFR, DER/EGFR, EGfr, EgfR, dEgfr, DER flb, ERBB1, TAF[II]250, mereletinib, wa-2, Torpedo/Egfr, CG17603, TAF[[II]], Degfr, AZD9291 mesylate, Egf, EFG-R, DmelCG17603, AZD-9291, Taf250, Errp, SR3-5, Erbb, DEGFR, l(2)57DEFa, l(2)05351, Der, DER, dEGFR, transforming growth factor-alpha receptor activity, DmHD-33, DER/torpedo, HER1, TAF230, TAF10.00.00.00.00.0falsescRNAseq of EGFR-mut PC9 cells control or treated for 24h or 72h with osimertinibscRNAseq of EGFR-mut PC9 cells control or treated for 24h or 72h with osimertinib2021-07-192021-07-19PRJEB399569606